Olema Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; filed May 9, 2023. Olema is a clinical-stage biopharmaceutical company developing targeted therapies for women’s cancers, primarily breast cancer. It has no approved products and generated no product revenue.
Financial and operating performance
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $22.8 million | $16.0 million |
| General and administrative expense | $6.8 million | $7.2 million |
| Total operating expenses | $29.6 million | $23.3 million |
| Net loss | $28.3 million | $23.0 million |
| Basic and diluted net loss per share | $0.70 | $0.58 |
| Net cash used in operating activities | $20.4 million | $17.9 million |
Cash, cash equivalents and marketable securities totaled $186.0 million at March 31, 2023, versus $204.4 million at December 31, 2022. Current assets were $189.4 million and current liabilities $19.4 million. The filing reports no debt outstanding. No meaningful operating margin is available because the company has no revenue.
Research and development expense rose $6.8 million, primarily from OP-1250 clinical development and manufacturing, other research and discovery costs, and personnel costs, including restructuring charges. G&A decreased $0.5 million, reflecting lower corporate and personnel costs, partly offset by restructuring charges. Interest income increased to $1.3 million from $0.2 million. Net loss widened by $5.3 million.
Investing activities provided $37.4 million, mainly reflecting marketable-security maturities net of purchases; financing activities provided $0.2 million from stock-option exercises. Cash and cash equivalents increased by $17.2 million during the quarter. Accumulated deficit was $237.3 million.
Business developments, outlook and risks
- OP-1250, an oral estrogen-receptor antagonist and degrader, is being evaluated in Phase 1/2 monotherapy and combination studies for ER-positive, HER2-negative advanced or metastatic breast cancer. Combinations include palbociclib, ribociclib and alpelisib.
- Following a March 2023 restructuring and portfolio prioritization, Olema said it would focus resources on later-stage clinical development of OP-1250. The workforce was reduced by approximately 25%. The company reported approximately $2.8 million in one-time charges, including $2.7 million of cash expenditures.
- Management expected the March 31 cash and investment balance to fund planned operating expenses and capital expenditures into 2025. The company expects continuing losses and says substantial additional funding will be needed; future financing may dilute shareholders or require restrictive terms or rights concessions.
- Management anticipated presenting Phase 2 monotherapy data in the second half of 2023, Phase 2 palbociclib-combination results in Q2 2023, and Phase 1b ribociclib-combination results in the second half of 2023. These are expectations, not guaranteed milestones.
- OP-1250 had FDA Fast Track designation for a specified metastatic breast cancer population. The filing cautions that designation does not guarantee faster review or approval. Clinical efficacy, safety, enrollment, manufacturing, regulatory approval, competition and commercialization remain uncertain.
- The filing cites geopolitical and macroeconomic uncertainty, inflation, interest-rate changes, bank and financial-market instability, and possible supply-chain disruption as potential risks. It also highlights dependence on third-party manufacturers and clinical research organizations. Three patients in the Phase 1a study had investigator-attributed grade 4 neutropenia; two had fever and neutropenia.
- The company reported no material pending litigation and no material changes to its disclosed commitments outside the ordinary course. Management concluded disclosure controls and procedures were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether OP-1250 trial data, enrollment and safety support the stated development plans and anticipated milestones.
- Whether the projected cash runway into 2025 remains achievable as development spending and restructuring effects evolve.
- The actual cash costs, savings and operational effects of the workforce reduction and portfolio prioritization.
- Future financing needs, potential dilution, and any changes to collaboration, licensing or manufacturing arrangements.
- Whether clinical, regulatory, competitive or macroeconomic developments materially alter the company’s plans or risk profile.